In times past, a pharmaceutical chemist’s main focus was to synthesize novel molecules to treat diseases. Today, an increasingly popular alternative is to re-engineer an existing drug—and continually improve it even after FDA approval. That’s how Robert D’Amato, MD, PhD, developed Pomalyst®, recently approved to treat multiple myeloma and the most potent analog to date of thalidomide.
Thalidomide has its own fascinating history. Originally developed by Chemie Grünenthal GmbH in the 1950s, it was the result of a search for an anti-anxiety drug to compete with Valium, and was approved for use in Europe as a sleep aid and depression treatment. Eventually, doctors found it useful for treating nausea, and started prescribing it off-label to pregnant women with morning sickness.
The results were disastrous. Thalidomide turned out to be a teratogen, causing severe birth defects. Full story »
In a four-way collaboration, skin cells from patients with autism will be used to make pluripotent stem cells. These will be made into neurons -- for study of what goes awry at the cellular level in autism, and for testing of drugs. (Miserlou/Wikimedia Commons)
In recent years, creative new partnerships have demonstrated big pharma’s recognition that academic medical centers hold many important cards in clinical research: scientific expertise, animal models of disease, patient samples and phenotypic data.
Increasingly, these partnerships involve academic and company researchers developing joint grant proposals in targeted areas, selected (by joint agreement) for company sponsorship. Some, like the Immune Disease Institute’s $25M arrangement with GlaxoSmithKline, are specific to one academic institution; others, like Pfizer’s Centers for Therapeutic Innovation (CTI) program, provide the same resources under the same deal structure to multiple institutions. Each new deal advances the interaction and understanding between academia and pharma around the common goal of finding new compounds and bringing them to clinic.
Now, in an exciting twist on its track record of partnerships with academic institutions, Roche has brought together three Harvard-affiliated organizations to screen and identify new drugs for the treatment of autism spectrum disorders (ASDs). Full story »
Even a small idea, given a small boost, can have a high impact. (Rick Kimpel/Flickr)
When I tell people I work at the Technology and Innovation Development Office at Children’s (TIDO), they usually think I work to commercialize patented blockbuster drug candidates. But many of the most satisfying projects I help promote are innovations that don’t involve as much risk, time and investment, yet make a big difference for patients. Commercializing these innovations can help the greater good, and is part of what propels me to work at a licensing office at a pediatric hospital.
And sometimes it doesn’t take much to help them along.
Sometimes promoting a non-money-maker is just the right thing to do. (Photo: iChaz/Flickr)
An article popped up in my Google alerts that gave me some excitement. A survey from the Association of University Technology Managers, reported in Mass High Tech, placed Children’s Hospital Boston fifth in licensing income among all U.S. hospitals. We were ranked just below the Mayo Clinic, which has more than double the research funding of Children’s. Massachusetts General Hospital was second on the list and Brigham and Women’s was eighth.*
I don’t often get to see quick financial results from my work (I’m the marketing and communications specialist in Children’s Technology and Innovation Development Office (TIDO), which licenses the Hospital’s technologies). But what I do get to see regularly is just as important to our mission: small advances that barely impact the hospital’s bottom line but have a large significance to our patients. Full story »
Streptococcus pneumoniae kills over a million young children a year, most of them in the developing world. Yet currently available pneumococcal vaccines are only effective against strains circulating in Europe and the US. How can we make affordable vaccines that work globally? Full story »